Biotech, Osteoporosis, RNA Interference
MDRNA Gets Tentative FDA Approval
Luke Timmerman 12/15/08
MDRNA (NASDAQ: MRNA), a Bothell, WA-based biotech company, said today it received tentative FDA approval of a generic version of calcitonin nasal spray for osteoporosis. The company can get full FDA approval in June, when a 180-day exclusivity period expires for Apotex, another generic maker. MDRNA now focuses on developing RNA interference drugs, not nasal sprays. It is evaluating options on what to do with the osteoporosis drug.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
